Recent drug approvals for acute myeloid leukemia

Catherine Lai, Kimberley Doucette, Kelly Norsworthy, Catherine Lai, Kimberley Doucette, Kelly Norsworthy

Abstract

Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, with an incidence that increases with age, and a generally poor prognosis. The disease is clinically and genetically heterogeneous, and recent advances have improved our understanding of the cytogenetic abnormalities and molecular mutations, aiding in prognostication and risk stratification. Until recently, however, therapeutic options were mostly limited to cytotoxic chemotherapy. Since 2017, there has been an explosion of newly approved treatment options both nationally and internationally, with the majority of new drugs targeting specific gene mutations and/or pivotal cell survival pathways. In this review article, we will discuss these new agents approved for the treatment of AML within the last 2 years, and will outline the mechanistic features and clinical trials that led to their approvals.

Keywords: Acute myeloid leukemia; Newly approved drugs; Novel treatments.

Conflict of interest statement

CL has served on an advisory board for Agios, Daiichi-Sankyo, and Jazz Pharmaceuticals and as a speaker for Astellas and Jazz Pharmaceuticals. KD and KN declare that they have no competing interests.

References

    1. Surveillance, E., and End Results (SEER) Program () SEER*Stat Database: incidence—SEER 9 Regs Research Data, Nov 2017 Sub (1973–2015) <Katrina/Rita Population Adjustment> − Linked To County Attributes - Total U.S., 1969–2016 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2018, based on the November 2017 submission.
    1. Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–1152. doi: 10.1056/NEJMra1406184.
    1. Deschler B, et al. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica. 2006;91(11):1513–1522.
    1. Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487–494. doi: 10.1200/JCO.2010.30.1820.
    1. Lichtman MA. A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3. Blood Cells Mol Dis. 2013;50(2):119–130. doi: 10.1016/j.bcmd.2012.10.005.
    1. Lowenberg B, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364(11):1027–1036. doi: 10.1056/NEJMoa1010222.
    1. Burnett AK, et al. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015;125(25):3878–3885. doi: 10.1182/blood-2015-01-623447.
    1. Karp JE, et al. In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia. Blood. 1989;73(1):24–30.
    1. Norsworthy KJ, et al. Timed sequential therapy for acute myelogenous leukemia: results of a retrospective study of 301 patients and review of the literature. Leuk Res. 2017;61:25–32. doi: 10.1016/j.leukres.2017.08.009.
    1. Geller RB, et al. A two-step timed sequential treatment for acute myelocytic leukemia. Blood. 1989;74(5):1499–1506.
    1. Herzig RH, et al. High-dose cytosine arabinoside therapy for refractory leukemia. Blood. 1983;62(2):361–369.
    1. Jen EY, et al. FDA approval: Gemtuzumab Ozogamicin for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia. Clin Cancer Res. 2018;24(14):3242–3246. doi: 10.1158/1078-0432.CCR-17-3179.
    1. Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood. 2010;116(24):5089–5102. doi: 10.1182/blood-2010-04-261867.
    1. Kelly LM, et al. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood. 2002;99(1):310–318. doi: 10.1182/blood.V99.1.310.
    1. Kottaridis PD, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98(6):1752–1759. doi: 10.1182/blood.V98.6.1752.
    1. Whitman SP, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 2001;61(19):7233–7239.
    1. Thiede C, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326–4335. doi: 10.1182/blood.V99.12.4326.
    1. Stone RM, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–464. doi: 10.1056/NEJMoa1614359.
    1. Stone RM, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005;105(1):54–60. doi: 10.1182/blood-2004-03-0891.
    1. Knapper S, et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood. 2006;108(10):3262–3270. doi: 10.1182/blood-2006-04-015560.
    1. Fischer T, et al. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol. 2010;28(28):4339–4345. doi: 10.1200/JCO.2010.28.9678.
    1. DeAngelo DJ, et al. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood. 2006;108(12):3674–3681. doi: 10.1182/blood-2006-02-005702.
    1. Fiedler W, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood. 2005;105(3):986–993. doi: 10.1182/blood-2004-05-1846.
    1. Zhang W, et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst. 2008;100(3):184–198. doi: 10.1093/jnci/djm328.
    1. Smith BD, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood. 2004;103(10):3669–3676. doi: 10.1182/blood-2003-11-3775.
    1. Cortes JE, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol. 2013;31(29):3681–3687. doi: 10.1200/JCO.2013.48.8783.
    1. Perl AE, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017;18(8):1061–1075. doi: 10.1016/S1470-2045(17)30416-3.
    1. Rydapt Prescribing Information. 2017; Available from: .
    1. Weisberg E, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 2002;1(5):433–443. doi: 10.1016/S1535-6108(02)00069-7.
    1. Ikegami Y, Yano S, Nakao K. Antitumor effect of CGP41251, a new selective protein kinase C inhibitor, on human non-small cell lung cancer cells. Jpn J Pharmacol. 1996;70(1):65–72. doi: 10.1254/jjp.70.65.
    1. Levis M, et al. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood. 2006;108(10):3477–3483. doi: 10.1182/blood-2006-04-015743.
    1. Stone RM, et al. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia. 2012;26(9):2061–2068. doi: 10.1038/leu.2012.115.
    1. Levis MJ, et al. Development of a novel next-generation sequencing (NGS)-based assay for measurable residual disease (MRD) in &lt;em&gt;FLT3&lt;/em&gt;-ITD AML and its potential clinical application in patients treated with chemotherapy plus FLT3 inhibitors. Blood. 2018;132(Suppl 1):1459.
    1. Vyxeos Prescribing Information. 2017; Available from: .
    1. Lancet JE, et al. Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. J Clin Oncol. 2016;34:7000–15_suppl. doi: 10.1200/JCO.2016.34.15_suppl.7000.
    1. IDHIFA Prescribing Information. 2017; Available from: . [cited 2018 December 20]
    1. Stein EM, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722–731. doi: 10.1182/blood-2017-04-779405.
    1. Mylotarg Prescribing Information. 2018; Available from: .
    1. Bross PF, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7(6):1490–6.
    1. Norsworthy KJ, et al. FDA approval summary: Mylotarg for treatment of patients with relapsed or refractory CD33-positive acute myeloid leukemia. Oncologist. 2018;23(9):1103–1108. doi: 10.1634/theoncologist.2017-0604.
    1. Xospata Prescribing Information. 2019; Available from: .
    1. Daurismo Prescribing Information. 2018; Available from: .
    1. Lee B, Onofrei CD, Sheski F. The culprit midostaurin in a case of drug-induced pneumonitis, in D35. Drug induced lung disease: case reports: American Thoracic Society; 2018. p. A6647. .
    1. Venclexta Prescribing Information. 2018; Available from: .
    1. Rydapt Product Information. 2017 [cited 2019 June 28]; Available from: .
    1. Midostaurin Medical Review(s). 2017 [cited 2019 June 28]; Available from: .
    1. Larson RA, et al. An analysis of maintenance therapy and post-midostaurin outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for newly diagnosed acute myeloid leukemia (AML) patients with <em>FLT3</em> mutations. 2017;130(Suppl 1):145. .
    1. Maziarz RTT, et al. Radius: a phase 2 randomized trial investigating standard of care ± midostaurin after allogeneic stem cell transplant in <em>FLT3</em>−ITD-mutated AML. 2018;132(Suppl 1):662. .
    1. Perl AE, et al. Final results of the Chrysalis trial: a first-in-human phase 1/2 dose-escalation, dose-expansion study of Gilteritinib (ASP2215) in patients with relapsed/refractory acute myeloid leukemia (R/R AML) Blood. 2016;128(22):1069.
    1. Perl A, Giovanni M, Jorge C, Andreas N, Berman E, Stefania P, Pau M, Baer Maria R, Larson Richard A, Celalettin U, Francesco F, Antonio DS, Robert S, Rebecca O, Margaret K, Fabio C, Wen-Chien C, Nikolai P, Christian R, Hisayuki Y, Naoko H, Sung-Soo Y, Je-Hwan L, Timothy P, Fathi Amir T, Chaofeng L, Xuan L, Erkut B, Levis Mark J. Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial. Atlanta, GA: AACR: Proceedings of the 110th Annual Meeting of the American Association for Cancer Research; 2019.
    1. Sexauer A, et al. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood. 2012;120(20):4205–4214. doi: 10.1182/blood-2012-01-402545.
    1. Fathi AT, et al. FLT3 inhibitor-induced neutrophilic dermatosis. Blood. 2013;122(2):239–242. doi: 10.1182/blood-2013-01-478172.
    1. Varadarajan N, et al. FLT3 inhibitor-associated neutrophilic dermatoses. JAMA Dermatol. 2016;152(4):480–482. doi: 10.1001/jamadermatol.2015.6121.
    1. Patel KP, et al. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol. 2011;135(1):35–45. doi: 10.1309/AJCPD7NR2RMNQDVF.
    1. Ward PS, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17(3):225–234. doi: 10.1016/j.ccr.2010.01.020.
    1. Yang H, et al. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. Clin Cancer Res. 2012;18(20):5562–5571. doi: 10.1158/1078-0432.CCR-12-1773.
    1. Stein EM, et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2019;133(7):676–687. doi: 10.1182/blood-2018-08-869008.
    1. Enasidenib Multi-Discipline Review/Summary, Clinical, Non-Clinical. 2017 December 12, 2018]; Available from: .
    1. Norsworthy KJ, M Flora, Ward Ashley F, Przepiorka Donna, Deisseroth Albert B, Farrell Ann T, Pazdur Richard, Incidence of Differentiation Syndrome with Ivosidenib (IVO) and Enasidenib (ENA) for Treatment of Patients with Relapsed or Refractory (R/R) Isocitrate Dehydrogenase (IDH)1- or IDH2-Mutated Acute Myeloid Leukemia (AML): A Systematic Analysis By the U.S. Food and Drug Administration (FDA). ASH Annual Meeting, 2018. Session 615: Oral Presentation.
    1. NDA multidisciplinary review and evaluation . Enasidenib. Center for drug evaluation and research. 2017.
    1. Tibsovo prescribing information. 2019; Available from: .
    1. Norsworthy KJ, et al. FDA approval summary: Ivosidenib for relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-1 mutation. Clin Cancer Res. 2019; p. clincanres.3749.2018
    1. DiNardo CD, et al. Durable remissions with Ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386–2398. doi: 10.1056/NEJMoa1716984.
    1. TIBSOVO Prescribing Information. 2018 [cited 2018 December 20]; Available from: .
    1. Dinardo CD, et al. Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML) J Clin Oncol. 2019;37(15_suppl):7011.
    1. Pan R, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014;4(3):362–375. doi: 10.1158/-13-0609.
    1. Konopleva M, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006;10(5):375–388. doi: 10.1016/j.ccr.2006.10.006.
    1. Tsao T, et al. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Ann Hematol. 2012;91(12):1861–1870. doi: 10.1007/s00277-012-1537-8.
    1. Konopleva M, et al. Efficacy and biological correlates of response in a phase II study of Venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106–1117. doi: 10.1158/-16-0313.
    1. DiNardo CD, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17. doi: 10.1182/blood-2018-08-868752.
    1. Lancet JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional Cytarabine plus Daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684–2692. doi: 10.1200/JCO.2017.77.6112.
    1. Lancet JE, et al. Efficacy and safety of CPX-351 versus 7+3 in older adults with secondary acute myeloid leukemia: combined subgroup analysis of phase 2 and phase 3 studies. Blood. 2017;130(Suppl 1):2657.
    1. Tardi P, et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res. 2009;33(1):129–139. doi: 10.1016/j.leukres.2008.06.028.
    1. Cortes JE, et al. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: phase 2 study results. Am J Hematol. 2018;93(11):1301–1310. doi: 10.1002/ajh.25238.
    1. Cortes JE, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2018;
    1. Aberger F, et al. Acute myeloid leukemia - strategies and challenges for targeting oncogenic hedgehog/GLI signaling. Cell Commun Signal. 2017;15(1):8. doi: 10.1186/s12964-017-0163-4.
    1. Castaigne S, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508–1516. doi: 10.1016/S0140-6736(12)60485-1.
    1. Wei AH, et al. Venetoclax combined with low-dose Cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J Clin Oncol. 2019;37(15):1277–1284. doi: 10.1200/JCO.18.01600.
    1. Wei A, et al. Venetoclax with low-dose Cytarabine induces rapid, deep, and durable responses in previously untreated older adults with AML ineligible for intensive chemotherapy. Blood. 2018;132(Suppl 1):284.
    1. Xospata Multi-Discipline Review/Summary, Clinical, Non-Clinical. 2018; Available from: .
    1. Perl AE, et al. Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial. in AACR Annual Meeting, vol. 2019. AACR: Atlanta; 2019. .
    1. Taksin AL, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia. 2007;21(1):66–71. doi: 10.1038/sj.leu.2404434.
    1. Amadori S, et al. Gemtuzumab Ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial. J Clin Oncol. 2016;34(9):972–9. doi: 10.1200/JCO.2015.64.0060.
    1. Castaigne S, et al. Final analysis of the ALFA 0701 study. Blood. 2014;124(21):376.
    1. Norsworthy, K.J., et al., FDA approval summary: Glasdegib for newly diagnosed acute myeloid leukemia. Clin Cancer Res. 2019. 10.1158/1078-0432.CCR-19-0365. [Epub ahead of print].
    1. Ivosidenib Multi-Discipline Review/Summary, Clinical, Non-Clinical. 2018; Available from: .
    1. Wei A, et al. Phase 1/2 study of Venetoclax with low-dose Cytarabine in treatment-naive, elderly patients with acute myeloid leukemia unfit for intensive chemotherapy: 1-year outcomes. Blood. 2017;130(Suppl 1):890.
    1. Wei AS, Stephen A, Jing-Zhou H, Fiedler W, Lin TL, Walter RB, Enjeti AK, Hong W-J, Chyla B, Popovic R, Fakouhi K, Xu T, Hayslip J, Roboz GJ. Venetoclax with low-dose Cytarabine induces rapid, deep, and durable responses in previously untreated older adults with AML ineligible for intensive chemotherapy ASH annual meeting: session 615. 2018.
    1. Glasdegib Medical Review(s). 2018; Available from: .
    1. Krauss AC, et al. FDA approval summary: (Daunorubicin and Cytarabine) liposome for injection for the treatment of adults with high-risk acute myeloid leukemia. Clin Cancer Res. 2019;25(9):2685–2690. doi: 10.1158/1078-0432.CCR-18-2990.
    1. Vardiman JW, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–951. doi: 10.1182/blood-2009-03-209262.
    1. Arber DA, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi: 10.1182/blood-2016-03-643544.
    1. Granfeldt Østgård LS, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a National Population-Based Cohort Study. J Clin Oncol. 2015;33(31):3641–3649. doi: 10.1200/JCO.2014.60.0890.
    1. Feldman EJ, et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol. 2011;29(8):979–985. doi: 10.1200/JCO.2010.30.5961.
    1. Lancet JE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014;123(21):3239–3246. doi: 10.1182/blood-2013-12-540971.
    1. Sievers EL, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19(13):3244–3254. doi: 10.1200/JCO.2001.19.13.3244.
    1. Sievers EL, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 1999;93(11):3678–3684.
    1. Petersdorf SH, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854–4860. doi: 10.1182/blood-2013-01-466706.
    1. Delaunay J, et al. Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of aml patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study. Blood. 2011;118(21):79.
    1. Burnett AK, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369–377. doi: 10.1200/JCO.2010.31.4310.
    1. Burnett AK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol. 2012;30(32):3924–3931. doi: 10.1200/JCO.2012.42.2964.
    1. Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15(9):986–996. doi: 10.1016/S1470-2045(14)70281-5.
    1. Mylotarg Medical Review(s). 2017; Available from: .

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit